Posted: Monday, July 13, 2020
Abhishek Maiti, MBBS, of The University of Texas MD Anderson Cancer Center, discusses results of his study on a 10-day treatment with decitabine and venetoclax, the tolerability of the investigational regimen vs intensive chemotherapy, and the relative toxicity.